Skip to main content
. 2022 Feb 5;41(12):1752–1766. doi: 10.1038/s41388-022-02203-2

Fig. 8. LLC lung cancer cells harboring hydroxylase-inactive EGLN3 exhibited reduced tumor growth.

Fig. 8

A–E LLC stable cell line expressing hydroxylase-inactive R205K or harboring control vector (B, inset) were subcutaneously inoculated into mice. LLC tumors were dissected on day 21 after implantation. Shown are tumor formation rate (A), tumor growth rate (B), representative photograph of LLC tumors (C), tumor volume (D) and tumor mass (E) (n = 6). F, G Immunohistochemistry analysis and quantification of PCNA expression (F) and cleaved caspase 3 expression (G) in tumors. H β-galactosidase staining and quantification of senescence-associated β-galactosidase (SA-β-Gal). I–N Immunohistochemistry analysis and quantification of p16 expression (I), VEGF expression (J), CD31+ cells (K), macrophage content (L), CD25+ cells (M), and CD8+ cells (N) in tumors. O, P IB analysis of tumor proteins prepared from the control and R205K tumors for the expression of proteins (p53, p21, p16, and HIF1α). Q IB analysis of HIF1α expression in control and R205K LLC cells (n = 3). Arrow indicates the specific band. HPF high power field; IB immunoblotting; Casp3 Caspase 3; β-Gal β-galactosidase; SA-β-Gal senescence-associated β-galactosidase; HIF1α hypoxia-inducible factor 1α; *p < 0.05; **p < 0.01; ****p < 0.0001 by unpaired 2-tailed Student’s t test.